Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07783009 | An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer | temporarily not available | — | — | Genentech, Inc.INDUSTRY | 0 | Sep 14, 2026 | clinicaltrials |
| NCT04830202 | Expanded Access to Telisotuzumab Vedotin | temporarily not available | — | — | AbbVieINDUSTRY | 0 | May 13, 2026 | clinicaltrials |
| NCT07517315 | Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments | temporarily not available | — | — | Sun Pharma Advanced Research Company LimitedINDUSTRY | 7 | Apr 15, 2026 | clinicaltrials |
| NCT07319910 | Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)(PANOVA-3CA) | temporarily not available | — | — | NovoCure GmbHINDUSTRY | 0 | Jan 6, 2026 | clinicaltrials |
| NCT01297101 | Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy | temporarily not available | — | — | Shanghai Chest HospitalOTHER | 0 | Feb 16, 2011 | clinicaltrials |
Data updated 15 days agoSource updated Sep 14, 2026source: clinicaltrials